TY - JOUR
T1 - Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder
AU - Asgari, Nasrin
AU - Flanagan, Eoin P.
AU - Fujihara, Kazuo
AU - Kim, Ho Jin
AU - Skejoe, Hanne P.
AU - Wuerfel, Jens
AU - Kuroda, Hiroshi
AU - Kim, Su Hyun
AU - Maillart, Elisabeth
AU - Marignier, Romain
AU - Pittock, Sean J.
AU - Paul, Friedemann
AU - Weinshenker, Brian G.
PY - 2017
Y1 - 2017
N2 - Objective: To describe leptomeningeal blood-barrier impairment reflected by MRI gadoliniumenhanced lesions in patients with aquaporin-4 immunoglobulin G (AQP4-IgG)-positive neuromyelitis optica spectrum disorder (NMOSD). Methods: A retrospective case series of 11 AQP4-IgG-positive NMOSD patients with leptomeningeal enhancement (LME) were collected from 5 centers. External neuroradiologists, blinded to the clinical details, evaluated MRIs. Results: LME was demonstrated on postcontrast T1-weighted and fluid-attenuated inversion recovery images as a sign of leptomeningeal blood-barrier disruption and transient leakage of contrast agent into the subarachnoid space in 11 patients, 6 in the brain and 6 in the spinal cord. The patterns of LMEwere linear or extensive and were accompanied by periependymal enhancement in 5 cases and intraparenchymal enhancement in all cases. The location of LME in the spinal cord was adjacent to intraparenchymal contrast enhancement with involvement of a median number of 12 (range 5-17) vertebral segments. At the time of LME on MRI, all patients had a clinical attack such as encephalopathy (36%) and/or myelopathy (70%) with median interval between symptom onset and LME of 12 days (range 2-30). LMEoccurred in association with an initial area postrema attack (44%), signs of systemic infection (33%), or AQP4-IgG in CSF (22%) followed by clinical progression. LME was found at initial clinical presentation in 5 cases and at clinical relapses leading to a diagnosis of NMOSD in 6 cases. Conclusion: This study suggests that altered leptomeningeal blood barrier may be accompanied by intraparenchymal blood-brain barrier breakdown in patientswith AQP4-IgG-positive NMOSD during relapses.
AB - Objective: To describe leptomeningeal blood-barrier impairment reflected by MRI gadoliniumenhanced lesions in patients with aquaporin-4 immunoglobulin G (AQP4-IgG)-positive neuromyelitis optica spectrum disorder (NMOSD). Methods: A retrospective case series of 11 AQP4-IgG-positive NMOSD patients with leptomeningeal enhancement (LME) were collected from 5 centers. External neuroradiologists, blinded to the clinical details, evaluated MRIs. Results: LME was demonstrated on postcontrast T1-weighted and fluid-attenuated inversion recovery images as a sign of leptomeningeal blood-barrier disruption and transient leakage of contrast agent into the subarachnoid space in 11 patients, 6 in the brain and 6 in the spinal cord. The patterns of LMEwere linear or extensive and were accompanied by periependymal enhancement in 5 cases and intraparenchymal enhancement in all cases. The location of LME in the spinal cord was adjacent to intraparenchymal contrast enhancement with involvement of a median number of 12 (range 5-17) vertebral segments. At the time of LME on MRI, all patients had a clinical attack such as encephalopathy (36%) and/or myelopathy (70%) with median interval between symptom onset and LME of 12 days (range 2-30). LMEoccurred in association with an initial area postrema attack (44%), signs of systemic infection (33%), or AQP4-IgG in CSF (22%) followed by clinical progression. LME was found at initial clinical presentation in 5 cases and at clinical relapses leading to a diagnosis of NMOSD in 6 cases. Conclusion: This study suggests that altered leptomeningeal blood barrier may be accompanied by intraparenchymal blood-brain barrier breakdown in patientswith AQP4-IgG-positive NMOSD during relapses.
UR - http://www.scopus.com/inward/record.url?scp=85025150114&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85025150114&partnerID=8YFLogxK
U2 - 10.1212/NXI.0000000000000343
DO - 10.1212/NXI.0000000000000343
M3 - Article
AN - SCOPUS:85025150114
SN - 2332-7812
VL - 4
JO - Neurology: Neuroimmunology and NeuroInflammation
JF - Neurology: Neuroimmunology and NeuroInflammation
IS - 4
ER -